Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (Note: The metadata references "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on July 27, 2006. The report details the entry into material definitive agreements involving the acquisition of a reference laboratory and related intellectual property assets.
Key Financial Metrics and Transaction Details
The filing reports two distinct transactions completed on July 27, 2006:
- Acquisition of NTD Laboratories, Inc.: PerkinElmer Holdings, Inc. purchased the outstanding stock of NTD Laboratories, Inc., a reference laboratory specializing in prenatal risk assessment.
- Consideration for NTD: $48,950,000 in cash, subject to a post-closing adjustment based on working capital.
- Acquisition of Macri Technologies Assets: PerkinElmer Singapore Pte Ltd acquired certain assets, including global patents related to free beta Human Chorionic Gonadotropin.
- Consideration for Assets: $7,700,000 in cash.
- Total Cash Consideration: Approximately $56,650,000 (excluding potential working capital adjustments).
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company as a whole, as this is a current report focused on specific transactional events rather than periodic financial results.
Material Changes
The primary material change is the expansion of PerkinElmer's capabilities in prenatal risk assessment through the acquisition of NTD Laboratories and the associated patent portfolio from Macri Technologies. This represents a strategic shift or expansion into specific reference laboratory services and intellectual property holdings.
Outlook, Risks, and Contingencies
The filing notes that the agreements contain customary representations, warranties, covenants, and indemnities. A specific contingency exists regarding the purchase price for NTD Laboratories, which is subject to a post-closing adjustment based on the company's working capital as of the closing date. No specific forward-looking guidance or management commentary regarding future financial performance is included in this text.
Key Facts for Investor Verification
- Verify the final purchase price for NTD Laboratories after the working capital adjustment is calculated.
- Confirm the integration timeline and expected synergies from the NTD Laboratories and Macri Technologies acquisitions.
- Review the full text of the Stock Purchase Agreement (Exhibit 99.1) and Asset Purchase Agreement (Exhibit 99.2) for specific covenants and indemnities.
- Check subsequent filings for the impact of these acquisitions on PerkinElmer's consolidated financial statements.